


Treating EGFR+ NSCLC in 2020:

New approaches, optimal outcomes

Saturday, 23 November 2019 | 12:45–14:15
Hall 404, Level 4, Suntec Convention & Exhibition Centre
Singapore



CHAIRMAN

Hwai Loong Kong

Icon Cancer Centre
Singapore



SPEAKER

Tony Mok

The Chinese University
of Hong Kong
Hong Kong



SPEAKER

**Thanyanan
Reungwetwattana**

Mahidol University
Bangkok, Thailand



SPEAKER

Daniel Tan

National Cancer Centre
Singapore

TIME	TOPIC	FACULTY
12:45	Opening & welcome remarks	Hwai Loong Kong (Singapore)
12:50	Upfront strategy: Third-generation TKI as first-line therapy	Thanyanan Reungwetwattana (Thailand)
13:10	Sequencing strategy: First-or second- generation followed by third-generation TKI	Tony Mok (Hong Kong)
13:30	Combination strategy: EGFR TKI and chemotherapy/ anti-angiogenic combinations	Daniel Tan (Singapore)
13:45	Expert panel interactive forum	Hwai Loong Kong (Singapore) Tony Mok (Hong Kong) Thanyanan Reungwetwattana (Thailand) Daniel Tan (Singapore)
14:10	Closing remarks	Hwai Loong Kong (Singapore)

Complimentary lunch will be provided to symposium attendees.



Pfizer Private Limited

80 Pasir Panjang Road, #16-81/82, Mapletree Business City,
Singapore 117372
Tel: (65) 6403 8888 | Fax: (65) 6403 8868 | www.pfizer.com.sg

This symposium may contain information about investigational product(s)/ indication(s) which are yet to be approved in Singapore. For healthcare professionals only. More information is available upon request.